Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...

Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...

The drugmaker has shed nearly $180 billion in market cap after struggling to chart a new course as the COVID-19 pandemic ...

pharma titans like Pfizer and biotech upstarts. Novo Nordisk is developing a weight loss pill. In the early stage trial, Novo evaluated how patients fared when taking one or two 50 mg amycretin ...

Former executives of the pharmaceutical giant are backing a push by activist investor Starboard Value to turn aro ...

US hedge fund Starboard now holds 0.6% of Pfizer’s value as the drugmaker struggles with its post-pandemic financial ...

Pfizer Inc.’s experimental drug for cancer weight loss was shown to help patients regain weight in a mid-stage study, offering fresh promise for treating the dangerous muscle-wasting condition.

Roche provided early Phase 1 clinical trial data last week that showed its pill provided 6.1% weight loss over four weeks ... including Pfizer (PFE), Novo, and Lilly. Pfizer recently revealed ...

Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ...

Current health news highlights WeightWatchers offering a compound version of Novo Nordisk's obesity drug, Danco seeking FDA ...

The health news update discusses Washington state's abortion pill stockpile as a safeguard, BioAge's successful IPO, a ...

Pfizer recently revealed Phase 2 clinical ... Patients showed 13.1% weight loss after 12 weeks on the pill, compared to 6% after 12 weeks in Wegovy's early trial. Terns showed its early-stage ...